Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Study of Immunotherapy Treatment in People With Sarcoma

Conditions: Sarcoma

First Posted Date: 2023-11-02

Last Posted Date: 2024-10-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 250

Registration Number: NCT06113315

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center Suffolk- Commack (All Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Phase 1

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Lenvatinib
Drug: Pembrolizuma
Drug: Fulvestrant

First Posted Date: 2023-11-01

Last Posted Date: 2025-04-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 43

Registration Number: NCT06110793

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 4 locations

A Study of Avutometinib for People With Solid Tumor Cancers

Phase 1

Recruiting

Conditions: NF1
Low-grade Glioma
CNS Tumor, Adult
Optic Pathway Gliomas
Neuroblastoma
Solid Tumor, Adult
CNS Tumors
Plexiform Neurofibroma
Refractory Cancer
CNS Tumor, Childhood

Interventions: Drug: Avutometinib

First Posted Date: 2023-10-27

Last Posted Date: 2025-04-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT06104488

Locations: 🇺🇸
Children's Healthcare of Atlanta (Data Collection Only), Atlanta, Georgia, United States
🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: TPC
Drug: Enzalutamide
Drug: Mifepristone

First Posted Date: 2023-10-25

Last Posted Date: 2025-04-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 201

Registration Number: NCT06099769

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California San Francisco (Data collection only), San Francisco, California, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 9 locations

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Phase 2

Recruiting

Conditions: Multiple Myeloma
Monoclonal Gammopathy of Renal Significance

Interventions: Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Dexamethasone
Drug: Daratumumab

First Posted Date: 2023-10-16

Last Posted Date: 2025-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 61

Registration Number: NCT06083922

Locations: 🇺🇸
Tufts Medical Center (Data Collection Only), Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 7 locations

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Phase 2

Recruiting

Conditions: Adrenocortical Carcinoma
ACC
Metastatic Adrenocortical Carcinoma

Interventions: Radiation: Ablative Radiotherapy
Drug: Pembrolizumab

First Posted Date: 2023-10-04

Last Posted Date: 2025-04-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT06066333

Locations: 🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Suffolk-Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

A Study of Talquetamab for People with Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Talquetamab

First Posted Date: 2023-10-04

Last Posted Date: 2025-03-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT06066346

Locations: 🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM)

Not Applicable

Recruiting

Conditions: Multiple Myeloma, Smoldering

Interventions: Dietary Supplement: Probiotic
Dietary Supplement: Curcumin
Dietary Supplement: Omega-3
Other: Whole food, plant-based diet (WFPBD)

First Posted Date: 2023-09-28

Last Posted Date: 2025-04-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 200

Registration Number: NCT06055894

Locations: 🇺🇸
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States

and more 4 locations

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Phase 2

Recruiting

Conditions: Metastatic Neuroblastoma
High-risk Neuroblastoma
Neuroblastoma

Interventions: Biological: OPT-821 (QS-21)
Dietary Supplement: oral β-glucan

First Posted Date: 2023-09-28

Last Posted Date: 2025-05-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 94

Registration Number: NCT06057948

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States

and more 4 locations

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Phase 2

Recruiting

Conditions: Peritoneal Mesothelioma
Mesothelioma
Malignant Peritoneal Mesothelioma
Malignant Mesothelioma
Mesothelioma, Malignant

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2023-09-28

Last Posted Date: 2025-05-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT06057935

Locations: 🇺🇸
University of Chicago (Data Collection Only), Chicago, Illinois, United States
🇺🇸
University of Michigan (Data Collection Only), Ann Arbor, Michigan, United States
🇺🇸
University of Nebraska (Data collection only), Omaha, Nebraska, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy